Neurofilament Light Chain (NfL) in Neurodegenerative Diseases
Neurofilament light chain (NfL) is a structural protein that normally helps support the shape and function of brain cells. In Alzheimer’s disease, brain cells are damaged, which causes the brain to shrink (atrophy), and symptoms such as declining cognition (ability to think, reason, and remember) to occur.
When these brain cells are damaged, they release NfL into the bloodstream, which can then be detected in the blood plasma. So an increase of NfL levels in the plasma can possibly indicate an increase in damage to brain cells In fact, research has shown that blood plasma levels of NfL correlate directly with the severity of symptoms and pathology of Alzheimer’s disease. NfL levels have been shown to increase in preclinical Alzheimer’s disease, before symptoms appear, indicating neurodegeneration.
In people with Alzheimer’s disease, increased amounts of NfL in the blood correspond to decreased thinking ability (cognition) and function. They also correlate with mild cognitive impairment (MCI) and other hallmarks of Alzheimer’s disease like brain shrinkage (atrophy) and tau tangles on a PET scan. Moreover, high levels of NfL at the present can predict how much a person with Alzheimer’s disease will decline in terms of their physical and mental capacity in the future.
NfL is an established biomarker in Alzheimer’s disease, but it is not specific to Alzheimer’s disease. Since NfL is released any time that brain cells are damaged, that damage can be caused by other factors. Thus, NfL cannot be used for diagnosis of Alzheimer’s disease. However, in a person who has already been diagnosed, this protein may be used as a powerful tool for measuring and predicting disease progression.
@RISK8888 How do you read it as not good sign la? He says he will end up selling 20% of his TauRx holdings to take back his initial capital. 80% pure profit waiting for big pay day when approval obtained. BIG MONEY BIG MONEY la... :p
@ATK Damn, now lending interest rates climbing, hope you can tahan until year end. Yes I think UK will be first, the rest will fall in line like domino. Just need 1 state/country to approve.
How is Genting B valuing its 20% exposure in investment in Taurx? Is it at book cost or mark to market? Surely it can’t be mark to market as Genting would have much higher valuation!
Genting we all know is undervalued ……however the market is bad and Malaysian market has been very bad for some time. Let’s see if the results are much better and if management have been able control costs.
人要敢于幻想....敢于梦想,最后才有希望...实现梦想。if Genting were to achieve earnings of 400 millions in the upcoming quarterly report, it could potentially rise to 6.00..。 go go Genting
Some info. about Taurx from google: Where is TauRx located? Singapore, TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.
Who is the CEO of TauRx? Professor Claude Wischik For three decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to find an effective treatment for neurodegenerative disease. Professor Wischik is a board-certified psychiatrist and holder of a Chair in Mental Health at the University of Aberdeen.
TauRx’s deliver Alzheimer’s disease therapy results 17th July 2023 Company’s hydromethylthionine mesylate therapy reduced neurodegeneration during pivotal trial
TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial. . . Henrik Zetterberg, professor of neurochemistry at UCL Queen Square Institute of Neurology, concluded: “NfL is a well studied biomarker with wide applicability to different neurological disorders, including AD.
“Clinical practice has been waiting decades to uncover meaningful advancements to address unmet needs of people with AD. These new results further support the importance of NfL as an AD biomarker both for diagnosis and measurement of treatment effect.”
TauRx now intends to submit the HMTM results from LUCIDITY and previous trials for regulatory approval in the US, UK and several other territories.
The "private value" of USD200-300 has been mentioned for many years. TauRx is a 30 year old "company".
The news about submitting for regulatory approval is old news.
The trouble with Private value is that it's really worth nothing until someone else buys. Until then, all you have is speculations. And speculations that has lasted years and years. The wait can be long. The payoff might not be there. Don't buy GENTING just because it owned 20% of TauRx ... Buy GENTING for other reasons.
We are Taurx shareholders for a long time n we know the privately done transacted market prices. Was usd150/share 3 months ago, now at minimum usd200/share after NfL data. Buyers are expecting this NfL data to substantially improve our chance of securing FDA AA (see Tofersen's case link) + more upside next year during China deal. --------------------------
Thanks. Where/how are these private transactions reported to TauRx shareholders? When was the last transaction, price, number of shares?
“From other channel checks, we understand that TauRx shares are now transacting at a much higher US$200-US$300 each. We are told that since not all shareholders participated in the aforementioned rights issue and thus, did not receive the warrants, Genting may effectively get to raise its shareholding in TauRx from 20% for cheap,” it said.
Thanks that is helpful data. Dundee Corp on the Toronto Stock Exchange (TSX: DC.A) owns 3.2% of TauRx. If the USD$200 price is real, Dundee's investment in TauRx is worth 3x Dundee's current market cap. Dundee is currently carrying it's TauRx investment at US$45 they hold just over 1M TauRx shares.
Dundee owned and controlled by Jews with unfair ordinary shares voting rights (100:1). Ordinary shares kena "poisoned". Preference shareholders making profit, ordinary shareholders suffer. Becareful when you buy such stocks.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Havefun
384 posts
Posted by Havefun > 2023-08-15 15:08 | Report Abuse
Hahaha the other way for Genting house looks more like it past few many years